<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Economopoulos, T.</style></author><author><style face="normal" font="default" size="100%">Psyrri, A.</style></author><author><style face="normal" font="default" size="100%">Dimopoulos, M.A.</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">CEOP-21 versus CEOP-14 chemotherapy With or without rituximab for the first-line treatment of patients with aggressive lymphomas: Results of the HE22A99 trial of the hellenic cooperative oncology group (The Cancer Journal 2007 13 (327-334))</style></title><secondary-title><style face="normal" font="default" size="100%">Cancer Journal</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2007</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2007</style></date></pub-dates></dates><urls><web-urls><url><style face="normal" font="default" size="100%">https://www.scopus.com/inward/record.uri?eid=2-s2.0-67649960415&amp;doi=10.1097%2f01.PPO.0000298296.80949.32&amp;partnerID=40&amp;md5=fb87a37b1c06866590e8316f3ab00848</style></url></web-urls></urls><volume><style face="normal" font="default" size="100%">13</style></volume><pages><style face="normal" font="default" size="100%">403</style></pages><language><style face="normal" font="default" size="100%">eng</style></language><issue><style face="normal" font="default" size="100%">6</style></issue><notes><style face="normal" font="default" size="100%">Export Date: 21 February 2017</style></notes></record></records></xml>